BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Meng, Qingtao; Han, Jian; Wang, Peng; Jia, Chenxu; Guan, Mingyang; Zhang, Bolun; Zhao, Wenzhi

doi:10.1016/j.jbo.2024.100594

Journal of Bone Oncology

2024

DOI: 10.1016/j.jbo.2024.100594

|View full text |Cite

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Qingtao Meng,

Jian Han,

Peng Wang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Development of New N-{4-[(7-Chloro-5-methylpyrrolo[2,1-f] [1,2,4]triazin-4-yl)oxy]-3-fluorophenyl}benzenesulfonamide Analogues: Exploring Anticancer Potential through MerTK Inhibition

Dwivedi,

Rathod,

Sathe

et al. 2024

Synlett

View full text Add to dashboard Cite

Mer proto-oncogene tyrosine-protein kinase (MerTK), a part of TAM (TYRO3, AXL and MerTK) family, is directly correlated with metastasis and various types of cancers. The inhibition of this receptor tyrosine kinase is one of the promising therapeutic strategies, as chemotherapy has higher efficacy. Considering the pharmacophoric features of the active domain of MerTK and structural characteristics of investigational drug, BMS794833, we have designed new N-(4-((7-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy)-3-fluorophenyl)benzenesulfonamide analogues (BDS-001 to BDS-005). In cytotoxic studies, BDS-001 displayed significantly higher cytotoxicity than cisplatin. It showed IC50 values of 2.09 µM, 1.96 µM and 3.08 µM against A549, MCF-7 and MDA-MB-231 cancer cell lines, respectively. In DMPK studies, BDS-001 was most stable and displayed moderate MerTK inhibitory potential. Molecular docking studies were performed to corroborate the MerTK inhibition, and BDS-001 was gave the most significant docking score (-12.33 Kcal/mol). Docking interactions demonstrated that imine and amine group of 3-chloropyridine moiety of BMS794833 formed a hydrogen bond with main chain of ATP pocket residue Met674, while oxygen atoms of 4-oxo-1,4-dihydropyridine-3-carboxamide moiety established hydrogen bonds with Lys619 and Asp741 amino acid residues of allosteric pocket of MerTK protein. These promising results are evident that N-(4-((7-chloro-5-methylpyrrolo[2,1-f][1,2,4]triazin-4-yl)oxy)-3-fluorophenyl)benzenesulfonamide pharmacophore can provide potential insights in development of new MerTK inhibitors.

show abstract

Development of New N-{4-[(7-Chloro-5-methylpyrrolo[2,1-f] [1,2,4]triazin-4-yl)oxy]-3-fluorophenyl}benzenesulfonamide Analogues: Exploring Anticancer Potential through MerTK Inhibition

Dwivedi,

Rathod,

Sathe

et al. 2024

Synlett

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

BMS-794833 reduces anlotinib resistance in osteosarcoma by targeting the VEGFR/Ras/CDK2 pathway

Cited by 1 publication

References 42 publications

Development of New N-{4-[(7-Chloro-5-methylpyrrolo[2,1-f] [1,2,4]triazin-4-yl)oxy]-3-fluorophenyl}benzenesulfonamide Analogues: Exploring Anticancer Potential through MerTK Inhibition

Development of New N-{4-[(7-Chloro-5-methylpyrrolo[2,1-f] [1,2,4]triazin-4-yl)oxy]-3-fluorophenyl}benzenesulfonamide Analogues: Exploring Anticancer Potential through MerTK Inhibition

Contact Info

Product

Resources

About